Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

Krueger, 2001, The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation Patient-Membership Survey, Arch Dermatol, 137, 280 Schon, 2005, Psoriasis, N Engl J Med, 352, 1899, 10.1056/NEJMra041320 Nickoloff, 2006, What have we learned in dermatology from the biologic therapies?, J Am Acad Dermatol, 54, S143, 10.1016/j.jaad.2005.10.059 Sterry, 2004, Biological therapies in the systemic management of psoriasis, Br J Dermatol, 151, 3, 10.1111/j.1365-2133.2004.06070.x Cargill, 2007, A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes, Am J Hum Genet, 80, 273, 10.1086/511051 Duerr, 2006, A genome-wide association study identifies IL23R as an inflammatory bowel disease gene, Science, 314, 1461, 10.1126/science.1135245 Capon, 2007, Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis, Hum Genet, 122, 201, 10.1007/s00439-007-0397-0 Piskin, 2006, In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin, J Immunol, 176, 1908, 10.4049/jimmunol.176.3.1908 Hong, 1999, IL-12, independently of IFN-γ, plays a crucial role in the pathogenesis of a murine psoriasis-like skin disorder, J Immunol, 162, 7480, 10.4049/jimmunol.162.12.7480 Torti, 2007, Interleukin-12, interleukin-23, and psoriasis: current prospects, J Am Acad Dermatol, 57, 1059, 10.1016/j.jaad.2007.07.016 Krueger, 2007, A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis, N Engl J Med, 356, 580, 10.1056/NEJMoa062382 Kimball, 2008, Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial, Arch Dermatol, 144, 200, 10.1001/archdermatol.2007.63 Papp, 2008, Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2), Lancet, 371, 1675, 10.1016/S0140-6736(08)60726-6 Pocock, 1975, Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial, Biometrics, 31, 103, 10.2307/2529712 Fredriksson, 1978, Severe psoriasis—oral therapy with a new retinoid, Dermatologica, 157, 238, 10.1159/000250839 Finlay, 1994, Dermatology life quality index (DLQI)—a simple practical measure for routine clinical use, Clin Exp Dermatol, 19, 210, 10.1111/j.1365-2230.1994.tb01167.x Geng, 2005, Validation of immunoassays used to assess immunogenicity to therapeutic monoclonal antibodies, J Pharm Biomed Anal, 39, 364, 10.1016/j.jpba.2005.04.045 Gordon, 2005, Definitions of measures of effect duration for psoriasis treatments, Arch Dermatol, 141, 82, 10.1001/archderm.141.1.82 Smith, 2007, IL-23 is required for neutrophil homeostasis in normal and neutrophilic mice, J Immunol, 179, 8274, 10.4049/jimmunol.179.12.8274 Trinchieri, 2003, Interleukin-12 and the regulation of innate resistance and adaptive immunity, Nat Rev Immunol, 3, 133, 10.1038/nri1001 Krueger, 2002, The immunologic basis for the treatment of psoriasis with new biologic agents, J Am Acad Dermatol, 46, 1, 10.1067/mjd.2002.120568 Wilson, 2007, Development, cytokine profile and function of human interleukin 17-producing helper T cells, Nat Immunol, 8, 950, 10.1038/ni1497 Bruch-Gerharz, 1996, A proinflammatory activity of interleukin 8 in human skin: expression of the inducible nitric oxide synthase in psoriatic lesions and cultured keratinocytes, J Exp Med, 184, 2007, 10.1084/jem.184.5.2007 Nickoloff, 2007, Cracking the cytokine code in psoriasis, Nat Med, 13, 242, 10.1038/nm0307-242 Vanden Eijnden, 2005, IL-23 upregulates IL-10 and induces IL-17 synthesis by polyclonally activated naïve T cells in human, Eur J Immunol, 35, 469, 10.1002/eji.200425677 Zheng, 2007, Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis, Nature, 445, 648, 10.1038/nature05505 Nestle, 2004, The IL-12 family member p40 chain as a master switch and novel therapeutic target in psoriasis, J Invest Dermatol, 123, XIV, 10.1111/j.0022-202X.2004.23488.x Carlin, 2004, A 50% reduction in the psoriasis area and severity index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis, J Am Acad Dermatol, 50, 859, 10.1016/j.jaad.2003.09.014 Gelfand, 2006, Risk of myocardial infarction in patients with psoriasis, JAMA, 296, 1735, 10.1001/jama.296.14.1735 Neimann, 2006, Prevalence of cardiovascular risk factors in patients with psoriasis, J Am Acad Dermatol, 55, 829, 10.1016/j.jaad.2006.08.040 Fieschi, 2003, The role of interleukin-12 in human infectious diseases: only a faint signature, Eur J Immunol, 33, 1461, 10.1002/eji.200324038 de Jong, 1998, Severe mycobacterial and salmonella infections in interleukin-12 receptor-deficient patients, Science, 280, 1435, 10.1126/science.280.5368.1435 Philipp, 2006, The evaluation of psoriasis therapy with biologics leads to a revision of the current view of the pathogenesis of this disorder, Expert Opin Ther Targets, 10, 817, 10.1517/14728222.10.6.817 Stern, 2004, Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction, J Invest Dermatol Symp Proc, 9, 136, 10.1046/j.1087-0024.2003.09102.x Richards, 2006, Adherence to treatment in patients with psoriasis, J Eur Acad Dermatol Venereol, 20, 370, 10.1111/j.1468-3083.2006.01565.x